Welcome to LookChem.com Sign In|Join Free
  • or
Pteroic acid is a key intermediate in the synthesis of folic acid analogues and derivatives, obtained through the chemical conversion of folic acid via acetylation and subsequent deacetylation steps, yielding a product often contaminated with residual folic acid. The process involves side reactions such as pyrazine derivative formation and pyrimidine ring opening, with purification achievable through column chromatography. Its structural features include a pteridine core linked to a benzoic acid moiety, making it a versatile precursor in medicinal chemistry.

119-24-4

Post Buying Request

119-24-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

119-24-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 119-24-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,1 and 9 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 119-24:
(5*1)+(4*1)+(3*9)+(2*2)+(1*4)=44
44 % 10 = 4
So 119-24-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H12N6O3/c15-14-19-11-10(12(21)20-14)18-9(6-17-11)5-16-8-3-1-7(2-4-8)13(22)23/h1-4,6,16H,5H2,(H,22,23)(H3,15,17,19,20,21)

119-24-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (Y0001243)  Folic acid impurity D  European Pharmacopoeia (EP) Reference Standard

  • 119-24-4

  • Y0001243

  • 1,880.19CNY

  • Detail
  • Aldrich

  • (P1781)  Pteroicacid  ≥93%

  • 119-24-4

  • P1781-25MG

  • 741.78CNY

  • Detail
  • Aldrich

  • (P1781)  Pteroicacid  ≥93%

  • 119-24-4

  • P1781-50MG

  • 1,289.34CNY

  • Detail
  • Aldrich

  • (P1781)  Pteroicacid  ≥93%

  • 119-24-4

  • P1781-100MG

  • 2,237.04CNY

  • Detail

119-24-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}benzoic acid

1.2 Other means of identification

Product number -
Other names Pteroic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:119-24-4 SDS

119-24-4Related news

Determination of PTEROIC ACID (cas 119-24-4) by high-performance thin-layer chromatography: Contribution to the investigation of 7,8-dihydropteroate synthase09/03/2019

A TLC method was developed that allows the evaluation of the 7,8-dihydropteroate synthase reaction via determination of the stable pteroic acid (PtA), obtained by chemical oxidation of the enzymatic product dihydropteroic acid (H2PtA). Using amino-bonded HPTLC plates and solution of 52% acetonit...detailed

Preparation and purification of PTEROIC ACID (cas 119-24-4) from folic acid09/02/2019

Crude pteroic acid, obtained by microbiological degradation of folic acid, has been purified by column chromatography on cellulose CF11, eluting with 0.1 M glycine buffer of pH 10.0, containing 0.15% w/v ascorbic acid and saturated with isoamyl alcohol.detailed

[92] Preparation and purification of PTEROIC ACID (cas 119-24-4) from pteroylglutamic acid (folic acid)09/01/2019

Publisher SummaryThis chapter describes the preparation and purification of pteroic acid from pteroylglutamic acid (folic acid). Pteroic acid can be prepared conveniently, by the removal of glutamic acid, from commercially available pteroyiglutamic acid, using a pteroylglutamic acid-degrading ps...detailed

Pharmaceutical NanotechnologyEnhanced cellular delivery of idarubicin by surface modification of propyl starch nanoparticles employing PTEROIC ACID (cas 119-24-4) conjugated polyvinyl alcohol08/30/2019

Enhanced intracellular internalization of the anti-cancer active idarubicin (IDA) was achieved through appropriate surface modification of IDA loaded propyl starch nanoparticles. This was conducted by synthesizing pteroic acid modified polyvinyl alcohol (ptPVA) and employing this stabilizer for ...detailed

119-24-4Relevant academic research and scientific papers

A step-wise synthetic approach is necessary to access γ-conjugates of folate: Folate-conjugated prodigiosenes

Figliola, Carlotta,Marchal, Estelle,Groves, Brandon R.,Thompson, Alison

, p. 14078 - 14092 (2019/05/21)

Despite the vast literature that describes reacting folic acid with a pharmacophore, this route is ineffective in providing the correct regioisomer of the resulting conjugate. We herein present a step-wise route to the preparation of nine folate conjugate

Synthesis and analysis of bacterial folate metabolism intermediates and antifolates

Dawadi, Surendra,Kordus, Shannon L.,Baughn, Anthony D.,Aldrich, Courtney C.

supporting information, p. 5220 - 5223 (2017/11/06)

The mechanism of action of para-aminosalicylic acid (PAS), a drug used to treat drug-resistant tuberculosis (TB), has been confirmed through the first synthesis and biochemical characterization of its active metabolite 7. The synthesis features the coupling of N2-acetyl-6-formylpterin obtained from the degradation of folic acid and appropriately functionalized arylamines to form Schiff bases. The sequential chemoselective reduction of the imine and pterin ring led to the formation of dihydrofolate analogue 7 and two other dihydropteroate species.

Site-specific folate conjugation to a cytotoxic protein

Smith, Bryan D.,Higgin, Joshua J.,Raines, Ronald T.

experimental part, p. 5029 - 5032 (2011/10/09)

Conjugation to folic acid is known to enhance the uptake of molecules by human cells that over-produce folate receptors. Variants of bovine pancreatic ribonuclease (RNase A) that have attenuated affinity for the endogenous ribonuclease inhibitor protein (

PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS

-

Page/Page column 47, (2009/01/20)

The present invention relates to processes for making epothilone compounds and analogs thereof, such as epi-epothilone A or epi-epothilone B, and aziridinyl-epothilone analogs.

POSITRON EMISSION TOMOGRAPHY IMAGING METHOD

-

Page/Page column 30-31, (2008/12/08)

Described herein are compositions and methods for diagnosing and/or monitoring pathogenic disease states using positron emission tomography, wherein the pathogenic cells uniquely express, preferentially express, or overexpress vitamin receptors. Also described herein are 18F conjugates of vitamins and vitamin receptor- binding analogs and derivatives.

AZIRIDINYL-EPOTHILONE COMPOUNDS

-

Page/Page column 29-30, (2008/06/13)

The present invention is directed to aziridinyl epothilone compounds as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof having the following Formula: wherein K is —O—, —S—, or —NR7—; A is —(CR8R9)—(CH2)m-Z- wherein Z is —(CHR10)—, —C(═O)—, —C(═O)—C(═O)—, —OC(═O)—, —N(R11)C(═O)—, —SO2—, or —N(R11)SO2—; B1 is hydroxyl or cyano and R1 is hydrogen or B1 and R1 are taken together to form a double bond; R2, R3, and R5 are, independently, hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; or R2 and R3 may be taken together with the carbon to which they are attached to form an optionally substituted cycloalkyl; R4 is hydrogen, alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, or substituted aryl; R6 is hydrogen, alkyl or substituted alkyl; R7, R8, R9, R10, R11 and R12 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, or substituted heteroaryl; and R13 is aryl, substituted aryl, heteroaryl or substituted heteroaryl.

The synthesis of folic acid, multiply labelled with stable isotopes, for bio-availability studies in human nutrition

Maunder, Peter,Finglas, Paul M.,Mallet, Anthony I.,Mellon, Fred A.,Aaqib Razzaque,Ridge, Brian,Vahteristo, Liisa,Witthoeft, Cornelia

, p. 1311 - 1323 (2007/10/03)

Two different methods for the synthesis of folic acid, which are suitable for the incorporation of compounds multiply labelled with stable isotopes, are described. The first method is based on the use of a novel reductive amination to link 2-acetyIamino-4-hydroxy-6-formylpteridine withp-aminobenzoyl-L-glutamic acid. The second method is based on the penultimate formation of an amide bond between Ar-2-acetyl-Ar-10-trifluoroacetyIpteroic acid and dimethyl L-glutamate. Both methods have been used to transform [13C6]aniline into folic acid, labelled with [13C6] in the p-aminobenzoate moiety, and [3,3,4,4-2H4]-L-glutamic acid into folic acid, labelled with [2H4] in the glutamate moiety. Doubly labelled [13C6,2H 4]-p-aminobenzoyl-L-glutamate has also been prepared by the former method.

Efficient syntheses of pyrofolic acid and pteroyl azide, reagents for the production of carboxyl-differentiated derivatives of folic acid

Luo, Jin,Smith, Michael D.,Lantrip, Douglas A.,Wang, Susan,Fuchs

, p. 10004 - 10013 (2007/10/03)

Reaction of folic acid (1) with excess trifluoroacetic anhydride provides access to both the previously unknown N10-(trifluoroacetyl)pyrrofolic acid (8) and pyrofolic acid (9). Reaction of either of these materials with hydrazine selectively affords pteroyl hydrazide (13), which may be oxidized to pteroyl azide (27) on a large scale (62% overall from I without the need for chromatography). Treatment of 27 with differentially protected glutamates provides a convenient and high-yielding synthesis of differentially protected, optically pure folates.

Synthesis and biological activity of novel folic acid analogues: Pteroyl- S-alkylhomocysteine sulfoximines

Harvison,Kalman

, p. 1227 - 1233 (2007/10/02)

The synthesis of a novel series of γ-substituted folic acid analogues, pteroyl-S-alkyl-DL-homocysteine (RS)-sulfoximines, and the corresponding S- methylhomocysteine sulfone is described. Side reactions of the sulfoximine groups of the amino acid ester reactants were considered. The correct structures of the isolated target compounds were confirmed by NMR and FAB/MS excluding other alternatives. The replacement of the γ-COOH of the glutamate moiety of folic acid with S-alkylsulfoximine groups of S-methylsulfone did not affect the substrate activity of the vitamin for dihydrofolate reductase. The resulting tetrahydrofolate analogues could serve as cofactors for the thymidylate synthase cycle of murine leukemia L1210 cells in situ. The analogues inhibited the growth of these cells in culture with 2 orders of magnitude lower IC50 values [(2-4) x 10-4 M] than the parent folic acid.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 119-24-4